HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.

AbstractOBJECTIVE:
To evaluate the cause of diagnostic errors in the visual interpretation of positron emission tomographic scans with fludeoxyglucose F 18 (FDG-PET) in patients with frontotemporal lobar degeneration (FTLD) and patients with Alzheimer disease (AD).
DESIGN:
Twelve trained raters unaware of clinical and autopsy information independently reviewed FDG-PET scans and provided their diagnostic impression and confidence of either FTLD or AD. Six of these raters also recorded whether metabolism appeared normal or abnormal in 5 predefined brain regions in each hemisphere-frontal cortex, anterior cingulate cortex, anterior temporal cortex, temporoparietal cortex, and posterior cingulate cortex. Results were compared with neuropathological diagnoses.
SETTING:
Academic medical centers.
PATIENTS:
Forty-five patients with pathologically confirmed FTLD (n=14) or AD (n=31).
RESULTS:
Raters had a high degree of diagnostic accuracy in the interpretation of FDG-PET scans; however, raters consistently found some scans more difficult to interpret than others. Unanimity of diagnosis among the raters was more frequent in patients with AD (27 of 31 patients [87%]) than in patients with FTLD (7 of 14 patients [50%]) (P=.02). Disagreements in interpretation of scans in patients with FTLD largely occurred when there was temporoparietal hypometabolism, which was present in 7 of the 14 FTLD scans and 6 of the 7 scans lacking unanimity. Hypometabolism of anterior cingulate and anterior temporal regions had higher specificities and positive likelihood ratios for FTLD than temporoparietal hypometabolism had for AD.
CONCLUSIONS:
Temporoparietal hypometabolism in FTLD is common and may cause inaccurate interpretation of FDG-PET scans. An interpretation paradigm that focuses on the absence of hypometabolism in regions typically affected in AD before considering FTLD is likely to misclassify a significant portion of FTLD scans. Anterior cingulate and/or anterior temporal hypometabolism indicates a high likelihood of FTLD, even when temporoparietal hypometabolism is present. Ultimately, the accurate interpretation of FDG-PET scans in patients with dementia cannot rest on the presence or absence of a single region of hypometabolism but rather must take into account the relative hypometabolism of all brain regions.
AuthorsKyle B Womack, Ramon Diaz-Arrastia, Howard J Aizenstein, Steven E Arnold, Nancy R Barbas, Bradley F Boeve, Christopher M Clark, Charles S DeCarli, William J Jagust, James B Leverenz, Elaine R Peskind, R Scott Turner, Edward Y Zamrini, Judith L Heidebrink, James R Burke, Steven T DeKosky, Martin R Farlow, Matthew J Gabel, Roger Higdon, Claudia H Kawas, Robert A Koeppe, Anne M Lipton, Norman L Foster
JournalArchives of neurology (Arch Neurol) Vol. 68 Issue 3 Pg. 329-37 (Mar 2011) ISSN: 1538-3687 [Electronic] United States
PMID21059987 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Adult
  • Age of Onset
  • Aged
  • Alzheimer Disease (diagnostic imaging, metabolism, pathology)
  • Brain (pathology)
  • Diagnosis, Differential
  • Diagnostic Errors
  • Female
  • Fluorodeoxyglucose F18
  • Frontotemporal Lobar Degeneration (diagnostic imaging, metabolism, pathology)
  • Humans
  • Image Processing, Computer-Assisted
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Observer Variation
  • Parietal Lobe (diagnostic imaging, metabolism, pathology)
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Temporal Lobe (diagnostic imaging, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: